Published in Cancer on October 01, 2007
MRI Guided Transurethral HIFU for Various Prostate Diseases (HIFU-PRO) | NCT03350529
Targeted radiotherapy with gold nanoparticles: current status and future perspectives. Nanomedicine (Lond) (2014) 1.22
Imaging of prostate cancer local recurrences: why and how? Eur Radiol (2009) 1.14
Salvage prostatectomy post-definitive radiation therapy: The Vancouver experience. Can Urol Assoc J (2015) 0.96
Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review. World J Urol (2012) 0.95
Management of biochemical recurrence after primary localized therapy for prostate cancer. Front Oncol (2012) 0.90
Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. J Urol (2012) 0.89
Role of focal salvage ablative therapy in localised radiorecurrent prostate cancer. World J Urol (2013) 0.89
Nanoparticle-based brachytherapy spacers for delivery of localized combined chemoradiation therapy. Int J Radiat Oncol Biol Phys (2015) 0.86
Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective Phase II study. Brachytherapy (2009) 0.85
Re-irradiation for salvage of prostate cancer failures after primary radiotherapy. World J Urol (2012) 0.85
Prostate gland lengths and iceball dimensions predict micturition functional outcome following salvage prostate cryotherapy in men with radiation recurrent prostate cancer. PLoS One (2013) 0.85
Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review. World J Urol (2016) 0.84
Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity. Radiat Oncol (2014) 0.83
Salvage cryotherapy for radiation-recurrent prostate cancer: outcomes and complications. Curr Urol Rep (2011) 0.82
Low temperature plasma: a novel focal therapy for localized prostate cancer? Biomed Res Int (2014) 0.81
Salvage brachytherapy in combination with interstitial hyperthermia for locally recurrent prostate carcinoma following external beam radiation therapy: a prospective phase II study. J Contemp Brachytherapy (2015) 0.81
Dynamic contrast enhanced MRI as a predictor of vascular-targeted photodynamic focal ablation therapy outcome in prostate cancer post-failed external beam radiation therapy. Can Urol Assoc J (2014) 0.80
Protocol-based image-guided salvage brachytherapy. Early results in patients with local failure of prostate cancer after radiation therapy. Strahlenther Onkol (2013) 0.80
Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators. Prostate Cancer (2014) 0.80
Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer. J Contemp Brachytherapy (2016) 0.79
The challenging landscape of medical device approval in localized prostate cancer. Nat Rev Urol (2015) 0.76
Salvage brachytherapy for locally recurrent prostate cancer after external beam radiotherapy. Asian J Androl (2015) 0.76
Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer. J Contemp Brachytherapy (2017) 0.76
Focal low-dose rate brachytherapy for the treatment of prostate cancer. Cancer Manag Res (2013) 0.75
Bladder neck contracture. Transl Androl Urol (2014) 0.75
Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy. J Contemp Brachytherapy (2010) 0.75
Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy. Radiat Oncol (2017) 0.75
Comparative cost-effectiveness of focal and total salvage (125)I brachytherapy for recurrent prostate cancer after primary radiotherapy. J Contemp Brachytherapy (2016) 0.75
Focal therapy for prostate cancer: the technical challenges. J Contemp Brachytherapy (2017) 0.75
Interstitial hyperthermia of the prostate in combination with brachytherapy : An evaluation of feasibility and early tolerance. Strahlenther Onkol (2013) 0.75
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA (2009) 7.25
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys (2007) 6.98
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med (2003) 4.30
Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA (2009) 3.10
Mortality after cure of testicular seminoma. J Clin Oncol (2004) 2.53
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46
Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: likelihood of positive surgical margin(s). Urology (2010) 2.31
Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer. Int J Radiat Oncol Biol Phys (2009) 2.27
Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer. BJU Int (2013) 2.18
Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy. Brachytherapy (2012) 2.05
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin (2010) 2.05
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol (2005) 2.05
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy. Int J Radiat Oncol Biol Phys (2013) 2.00
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol (2012) 1.86
Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology (2010) 1.83
Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys (2010) 1.70
Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer (2008) 1.66
Reducing metal artifacts in cone-beam CT images by preprocessing projection data. Int J Radiat Oncol Biol Phys (2006) 1.65
PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA (2007) 1.61
Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer (2010) 1.59
Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapy. J Urol (2011) 1.58
The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer (2014) 1.58
Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys (2009) 1.55
What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. Ann Intern Med (2012) 1.54
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol (2005) 1.54
Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. J Clin Oncol (2008) 1.52
Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. J Urol (2011) 1.52
Reducing stray radiation dose to patients receiving passively scattered proton radiotherapy for prostate cancer. Phys Med Biol (2008) 1.51
Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol (2003) 1.51
Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer (2013) 1.48
Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. J Clin Oncol (2002) 1.47
Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J (2012) 1.47
Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management. Cancer (2008) 1.46
Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys (2010) 1.44
Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy. J Urol (2010) 1.41
Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. Int J Radiat Oncol Biol Phys (2007) 1.40
Using patient-reported outcomes to assess and improve prostate cancer brachytherapy. BJU Int (2014) 1.39
Impact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer. Cancer (2013) 1.39
Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer. Cancer (2007) 1.37
Tissue-type plasminogen activator regulates the neuronal uptake of glucose in the ischemic brain. J Neurosci (2012) 1.31
A beam-specific planning target volume (PTV) design for proton therapy to account for setup and range uncertainties. Int J Radiat Oncol Biol Phys (2011) 1.31
Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol (2010) 1.29
Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys (2008) 1.27
The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma. Cancer (2005) 1.27
Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol (2007) 1.25
Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model. Int J Radiat Oncol Biol Phys (2010) 1.21
Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer (2006) 1.20
Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol (2006) 1.19
Patient-specific quality assurance for prostate cancer patients receiving spot scanning proton therapy using single-field uniform dose. Int J Radiat Oncol Biol Phys (2011) 1.19
A comprehensive comparison of IMRT and VMAT plan quality for prostate cancer treatment. Int J Radiat Oncol Biol Phys (2012) 1.19
Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.17
Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol (2012) 1.17
Silicone implant and primary breast ALK1-negative anaplastic large cell lymphoma, fact or fiction? Int J Clin Exp Pathol (2009) 1.16
Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience. Urology (2009) 1.15
Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol (2006) 1.13
Dosimetric comparison of four target alignment methods for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.09
An automatic CT-guided adaptive radiation therapy technique by online modification of multileaf collimator leaf positions for prostate cancer. Int J Radiat Oncol Biol Phys (2005) 1.05
Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer. Cancer (2006) 1.04
Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys (2012) 1.04
Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer (2011) 1.04
The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int (2010) 1.04
Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys (2009) 1.04
Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer (2006) 1.03
Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int (2011) 1.03
Evaluation of a contour-alignment technique for CT-guided prostate radiotherapy: an intra- and interobserver study. Int J Radiat Oncol Biol Phys (2004) 1.03
Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. Int J Radiat Oncol Biol Phys (2002) 1.02
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res (2004) 1.01
Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int J Radiat Oncol Biol Phys (2003) 1.01
Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. J Urol (2012) 1.01
Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys (2011) 1.00
Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.00
Quantification of prostate and seminal vesicle interfraction variation during IMRT. Int J Radiat Oncol Biol Phys (2008) 0.99
PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. Urology (2008) 0.99
Effectiveness of using fewer implanted fiducial markers for prostate target alignment. Int J Radiat Oncol Biol Phys (2009) 0.99
Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int (2010) 0.99
Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level. Cancer (2006) 0.98
Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol (2005) 0.98
Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy. Cancer (2003) 0.97
The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology (2009) 0.97
Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology (2006) 0.97
Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys (2009) 0.97